Venus Remedies jumps on securing marketing authorizations for Docetaxel in Israel, Cytarabine in Colombia

21 Dec 2023 Evaluate

Venus Remedies is currently trading at Rs. 400.00, up by 24.05 points or 6.40% from its previous closing of Rs. 375.95 on the BSE.

The scrip opened at Rs. 375.95 and has touched a high and low of Rs. 407.60 and Rs. 371.30 respectively. So far 42911 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 419.05 on 07-Dec-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.

Last one week high and low of the scrip stood at Rs. 401.30 and Rs. 371.40 respectively. The current market cap of the company is Rs. 537.35 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.03% and 57.21% respectively.

Venus Remedies has secured marketing authorizations for three variants of Docetaxel in Israel and Cytarabine 100MG in Colombia. The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify its commitment to advancing healthcare solutions globally.

Earlier, the company had unveiled a significant transformation of its consumer healthcare division, R3SET. This strategic pivot marks R3SET's foray into the wellness arena, coupled with the expansion of its pain management portfolio, showcasing the company's holistic approach to wellness solutions.

enus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

Venus Remedies Share Price

320.50 7.45 (2.38%)
07-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1507.00
Dr. Reddys Lab 6037.55
Cipla 1497.30
Zydus Lifesciences 1058.45
Lupin 1630.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.